Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A SCHWARTZ

Showing results (51-60 of 3,279) with videos related to

Pageof 328
Sort By:
Applied Optics|June 23, 2010
Laser ranging error budget for the TOPEX/POSEIDON satelliteJ A Schwartz
Biologics : Targets & Therapy|August 27, 2009
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease: An interview with David A Schwartz, 13 June 2007David A Schwartz
Explore (New York, N.Y.)|March 15, 2011
Trends that will affect your future … an appraisal of the illness profit systemStephan A Schwartz
Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia|March 23, 2011
Environmental genomics and human healthD A Schwartz
Drug Intelligence & Clinical Pharmacy|April 1, 1984
Post-doctoral education for pharmacy practice facultyM A Schwartz
Environmental Health Perspectives|May 29, 1999
Etiology and pathogenesis of airway disease in children and adults from rural communitiesD A Schwartz
Trends in Cell Biology|October 1, 1992
Transmembrane signalling by integrinsM A Schwartz
The Journal of Physiology|August 1, 1973
Responses of single rods in the retina of the turtleE A Schwartz
Oncology|January 1, 1979
Multiple persistent keratoacanthomasR A Schwartz
The Journal of Physiology|January 1, 1974
Responses of bipolar cells in the retina of the turtleE A Schwartz
Pageof 328

Showing results (51-60 of 3,279) with videos related to

Sort By:
Pageof 328
Applied Optics|June 23, 2010
Laser ranging error budget for the TOPEX/POSEIDON satelliteJ A Schwartz
Biologics : Targets & Therapy|August 27, 2009
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease: An interview with David A Schwartz, 13 June 2007David A Schwartz
Explore (New York, N.Y.)|March 15, 2011
Trends that will affect your future … an appraisal of the illness profit systemStephan A Schwartz
Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia|March 23, 2011
Environmental genomics and human healthD A Schwartz
Drug Intelligence & Clinical Pharmacy|April 1, 1984
Post-doctoral education for pharmacy practice facultyM A Schwartz
Environmental Health Perspectives|May 29, 1999
Etiology and pathogenesis of airway disease in children and adults from rural communitiesD A Schwartz
Trends in Cell Biology|October 1, 1992
Transmembrane signalling by integrinsM A Schwartz
The Journal of Physiology|August 1, 1973
Responses of single rods in the retina of the turtleE A Schwartz
Oncology|January 1, 1979
Multiple persistent keratoacanthomasR A Schwartz
The Journal of Physiology|January 1, 1974
Responses of bipolar cells in the retina of the turtleE A Schwartz
Pageof 328